Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs to Host Annual Research and Development Day in New York

06 Dec 2022 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

01 Dec 2022 17:34:16 By Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

07 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

02 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

28 Oct 2022 15:33:33 By Nasdaq GlobeNewswire

Y-mAbs Announces Pivotal Data for Omburtamab

03 Oct 2022 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

26 Sep 2022 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

01 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

30 Aug 2022 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

08 Aug 2022 16:05:02 By Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

02 Aug 2022 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs’ Announces Clearance of IND for GD2-SADA

12 Jul 2022 09:00:02 By Nasdaq GlobeNewswire

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

31 May 2022 09:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

26 May 2022 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

09 May 2022 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

03 May 2022 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

27 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of SADA Technology at AACR

08 Apr 2022 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

01 Apr 2022 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

24 Feb 2022 16:01:01 By Nasdaq GlobeNewswire